APA

Johnson M., Kumar P., Molina J., Rizzardini G., Cahn P., Bickel M., Mallolas J., Zhou Y., Morais C., Kumar S., Sklar P., Hanna G. J., Hwang C. & Greaves W. (20200218). Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. : Journal of acquired immune deficiency syndromes (1999).

Chicago

Johnson Margaret, Kumar Princy, Molina Jean-Michel, Rizzardini Giuliano, Cahn Pedro, Bickel Markus, Mallolas Josep, Zhou Yan, Morais Cristiana, Kumar Sushma, Sklar Peter, Hanna George J, Hwang Carey and Greaves Wayne. 20200218. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. : Journal of acquired immune deficiency syndromes (1999).

Harvard

Johnson M., Kumar P., Molina J., Rizzardini G., Cahn P., Bickel M., Mallolas J., Zhou Y., Morais C., Kumar S., Sklar P., Hanna G. J., Hwang C. and Greaves W. (20200218). Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. : Journal of acquired immune deficiency syndromes (1999).

MLA

Johnson Margaret, Kumar Princy, Molina Jean-Michel, Rizzardini Giuliano, Cahn Pedro, Bickel Markus, Mallolas Josep, Zhou Yan, Morais Cristiana, Kumar Sushma, Sklar Peter, Hanna George J, Hwang Carey and Greaves Wayne. Switching to Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate (DOR/3TC/TDF) Maintains HIV-1 Virologic Suppression Through 48 Weeks: Results of the DRIVE-SHIFT Trial. : Journal of acquired immune deficiency syndromes (1999). 20200218.